Travere Therapeutics (TVTX) Misses Q1 EPS by 17c

Travere Therapeutics (NASDAQ: TVTX) reported Q1 EPS of ($0.40), $0.17 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $127.2 million versus the consensus estimate of $137.34 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.

You May Also Be Interested In

• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Bandwidth launches platform for AI agents to access voice services